7th Nov 2007 07:01
AstraZeneca PLC07 November 2007 Not for release, publication or distribution directly or indirectly in or intothe United States, Canada, Australia or Japan AstraZeneca launches and prices a debut GBP 350 million sterling bond and a EUR 750 million eurobond AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard &Poor's, announces the successful pricing of a debut sterling bond for GBP 350million and a Euro 750 million eurobond transaction (the "Bonds"). The proceedsof the issue will be used for general corporate purposes and to repay a portionof the outstanding US commercial paper taken on in connection with theacquisition of MedImmune. Both transactions were issued under AstraZeneca PLC's Euro Medium Term Note(EMTN) programme. The sterling bond is a GBP 350 million, fixed rate issue witha coupon of 5.75% maturing 13 November 2031. The eurobond is a EUR 750 million,fixed rate issue with a coupon of 4.625% maturing12 November 2010. This transaction represents a continuation of the refinancing of the acquisitionof MedImmune Inc, following the $6.9 billion, 4-tranche SEC Global and EUR 750million debut eurobond transactions in September. The Bonds will be issued to institutional investors outside the US in accordancewith Regulation S of the U.S. Securities Act of 1933, as amended. The Bondswill be admitted to listing on the UKLA's Official List and to trading on theLondon Stock Exchange's Fixed Interest and Gilt Edged Market. About AstraZeneca AstraZeneca is a major international healthcare business engaged in theresearch, development, manufacture and marketing of prescription pharmaceuticalsand the supply of healthcare services. It is one of the world's leadingbio-pharmaceutical companies with healthcare sales of $26.47 billion and leadingpositions in sales of gastrointestinal, cardiovascular, neuroscience,respiratory, oncology and infection products. AstraZeneca is listed in the DowJones Sustainability Index (Global) as well as the FTSE4Good Index. 7 November 2007 Media Enquiries:Edel McCaffrey, Tel: +44 (0) 207 304 5034Steve Brown, Tel: +44 (0) 207 304 5033 Investor Relations:Mina Blair, Tel: +44 (0) 207 304 5084Jonathan Hunt, Tel: +44 (0) 207 304 5087Karl Hard, Tel: +44 (0) 207 304 5322Jorgen Winroth, Tel: +1 (212) 579 0506Ed Seage, Tel: +1 302 886 4065Pete Vozzo, (MedImmune) Tel: + 1 301-398-4358 This announcement is for information only and does not constitute an offer orinvitation to subscribe for or purchase any securities. The securities have not been, nor will they be, registered under the U.S.Securities Act of 1933, as amended (the "Securities Act"), and no securitiesshall be offered or sold in the United States or to U.S. persons (as those termsare defined in Regulation S under the Securities Act) absent registration or anapplicable exemption from the registration requirements of the Securities Act.There will be no public offering of the securities in the United States inconnection with this transaction. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca